Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024
Global Phase-3 study initiation expected in the second half of 2024
Global Phase-3 study initiation expected in the second half of 2024
KRKA holds 51% and Laurus Labs holds 49% shareholding
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Subscribe To Our Newsletter & Stay Updated